In non-adherent ovarian cancer cells, c-MET overexpression caused acquired resistance to cisplatin and paclitaxel through PI3K/AKT and extracellular signal-regulated kinase (ERK) 1/2 signaling [11]. Here, MET is linked to ovarian cancer.